Novo Nordisk reports strong sales growth in the first half of 2024

From GlobeNewswire: 2024-08-07 01:31:00

Novo Nordisk reported an 18% increase in operating profit to DKK 57.8 billion for the first half of 2024, driven by strong sales growth in North America and internationally. Sales within Diabetes and Obesity care saw significant increases, while Rare disease sales decreased. The company also received positive trial results for Mim8 and a positive CHMP opinion for an update of the Wegovy® label. For the 2024 outlook, sales growth is expected to be 22-28% at CER, and operating profit growth is expected to be 20-28% at CER.

Novo Nordisk’s CEO Lars Fruergaard Jørgensen stated that the company was pleased with the sales growth in the first half of 2024, driven by demand for GLP-1-based diabetes and obesity treatments. He emphasized the innovation within R&D, highlighting promising trial results for Mim8 and the positive label extension for Wegovy® in the EU.

Founded in 1923 and headquartered in Denmark, Novo Nordisk is a global healthcare company dedicated to defeating serious chronic diseases, focusing on diabetes. The company employs approximately 69,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen, while its ADRs are listed on the New York Stock Exchange.



Read more at GlobeNewswire:: Novo Nordisk’s sales increased by 24% in Danish kroner and